Arthneeti
DL

Dhansa Labs Ltd

Q2 FY27Fertilizers & Agrochemicals

Dhansa Labs Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Dhansa Labs Ltd Q2 FY27 key numbers

Revenue
Quarterly revenue from operations: Rs. 4,001.34 lakhs for Q2 2026, up from Rs. 3,988.63 lakhs in Q2 2025, showing a slight year-on-year increase.

As stated in Dhansa Labs Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.

Based on Dhansa Labs Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹23
Market cap₹61 Cr
P/E11.0

The short version

Quarterly revenue from operations: Rs. 4,001.34 lakhs for Q2 2026, up from Rs. 3,988.63 lakhs in Q2 2025, showing a slight year-on-year increase. Quarterly EBITDA: ₹1,924.2 Crore, up 9% YoY.

From Dhansa Labs Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.

How did Dhansa Labs' revenue grow in the September 2026 quarter?

  • Quarterly revenue from operations: Rs. 4,001.34 lakhs for Q2 2026, up from Rs. 3,988.63 lakhs in Q2 2025, showing a slight year-on-year increase.
  • Total income for Q2 2026: Rs. 4,002.44 lakhs compared to Rs. 3,999.05 lakhs in Q2 2025.

What happened to Dhansa Labs' margins in Q2 FY27?

Quarterly EBITDA: ₹1,924.2 Crore, up 9% YoY

Locked: what Dhansa Labs Ltd said on margins

Also locked on this page: fundraising

Free account, 30 seconds. No card needed.

What capex is Dhansa Labs planning?

  • The company allotted convertible equity warrants aggregating Rs. 4,999.99 lakhs during the year ended 31 March 2026, with Rs. 2,161.54 lakhs received as part consideration by 30 September 2026.
  • The money received against warrants has been utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure, and land-related advances.
  • The planned utilization supports ongoing capital expenditure but without explicit mention of project names, status, or completion dates.

Top-ranked in Fertilizers & Agrochemicals

Ranked on what management guided this quarter

Guidance-ranked
1Anya Polytech &
Rev 2Mar 1
2Insecticides India
Rev 2Mar 2
3
Rev 2Mar 3
4
Rev 2Mar 3
5
Rev 3Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Dhansa Labs raising money or cutting debt?

The company allotted 1,08,69,565 convertible equity warrants on a preferential basis at Rs. 46 per…

Locked: what Dhansa Labs Ltd said on fundraising

Also locked on this page: margins

Free account, 30 seconds. No card needed.

How big is Dhansa Labs' order book?

The investor presentation reports the following regarding orders: - **Order Inflow:** Rs. 1,864 crores during H1 FY27. - **Order Book:** Rs. 5,050 crores as of September 30, 2026. - **Pending Orders:** The order backlog stands at Rs. 5,050 crores. These figures are explicitly stated on page 14 under "Consolidated Statement of Cashflow" and related sections summarizing company performance and order status.

Dhansa Labs Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27

Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹31 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Fertilizers & Agrochemicals

All Q2 FY27 results | Fertilizers & Agrochemicals rankings

Continue your research

What Dhansa Labs's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Year-on-year revenue growth: Rs 70,254.28 Lakhs vs Rs 60,786.41 Lakhs (~15.6% increase) . Key results statement takeaways from Krishana Phoschem Ltd's Q2 FY27 e

  • Balaji Phosphates (Q2 FY27)

    Year-on-year growth for the half year (Standalone): ~31.4% increase (from Rs. Key results statement takeaways from Balaji Phosphates Ltd's Q2 FY27 results state

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Dhansa Labs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Dhansa Labs Ltd Q2 FY27 results?

Quarterly revenue from operations: Rs. 4,001.34 lakhs for Q2 2026, up from Rs. 3,988.63 lakhs in Q2 2025, showing a slight year-on-year increase. Quarterly EBITDA: ₹1,924.2 Crore, up 9% YoY.

What is Dhansa Labs Ltd share price analysis?

Dhansa Labs Ltd currently shows a neutral. The stock trades at a P/E of 11.0 with a market cap of ₹61 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dhansa Labs Ltd planning capital expenditure?

The company allotted convertible equity warrants aggregating Rs. 4,999.99 lakhs during the year ended 31 March 2026, with Rs. 2,161.54 lakhs received as part consideration by 30 September 2026.

Keep Dhansa Labs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.